

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: **Chen W. Liaw et al.**Serial No.: **Not yet assigned** Group Art Unit: **1646**Filed: **Concurrently herewith** Examiner: **Prema Maria Mertz**Title: **NUCLEIC ACID ENCODING HUMAN G PROTEIN-COUPLED RECEPTOR**

**EXPRESS MAIL INFORMATION**  
EXPRESS MAIL LABEL NO: EL964555223US  
DATE OF DEPOSIT: February 19, 2004

Mail Stop: Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the attached PTO/SB/08a, PTO/SB/08b, PTO-1449 and PTO-892 forms submitted herewith.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

Copies of the references cited on the attached PTO/SB/08a, PTO/SB/08b, PTO-1449 and PTO-892 forms can be found in the parent case, U.S. Serial No. 09/875,076, filed June 6, 2001.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

No first Official Action has yet been received and it is presumed that none has yet been mailed. No fee or certification is required. 37 C.F.R. § 1.97(b).

Respectfully submitted,



Michael A. Patané  
Regis. No. 42,982

Enclosures:

24 sheets attached

Dated: 02/19/2004

Cozen O'Connor  
1900 Market Street  
Philadelphia, PA 19103  
Tel: 215.665.2000  
Fax: 215.665.2013

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete If Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/875,076
<i>(use as many sheets as necessary)</i>		Filing Date	June 6, 2001
		First Named Inventor	C. Liaw et al.
		Art Unit	1646
		Examiner Name	Prema Maria Mertz
Sheet	1	of	2
		Attorney Docket Number	AREN-11.US9.DIV (0239)

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. 6 Applicant is to place a check mark here if English language Translation is attached.

place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>		<b>Complete if Known</b>	
		Application Number	09/875,076
		Filing Date	June 6, 2001
		First Named Inventor	C. Liaw et al.
		Group Art Unit	1646
		Examiner Name	Prema Maria Mertz
Sheet	2	of	2
		Attorney Docket Number	
		AREN-11.US9.DIV (0239)	

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Shee

1

2

**Attorney Docket Number**

**Complete If Known**

**Application Number** 09/875,076

**Filing Date** June 6, 2001

**First Named Inventor** Chen Liaw

Group Art Unit 1646

Examiner Name P. Mertz

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				<p><b>Complete if Known</b></p>	
<p>Application Number</p>		<p>09/875,076</p>			
<p>Filing Date</p>		<p>June 6, 2001</p>			
<p>First Named Inventor</p>		<p>Chen Liaw</p>			
<p>Group Art Unit</p>		<p>1646</p>			
<p>Examiner Name</p>		<p>P. Mertz</p>			
				<p>Attorney Docket Number</p>	
				<p>11.US9.DIV (AREN-0239)</p>	
Sheet	2	of	2		

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>AA</b>	Alla, S.A. et al., "Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies," <i>J. Biol. Chem.</i> , 1996, 271, 1748-1755	
	<b>AB</b>	Advenier, C. et al., "Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK <sub>2</sub> ) receptors," <i>Am. Rev. Respir. Dis.</i> , 1992, 146(5, Pt. 1), 1177-1181	
	<b>AC</b>	Alexander, W.S. et al., "Point mutations within the dimer interfact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , 1995, 14(22), 5569-5578	
	<b>AD</b>	Arvanitakis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , 1997, 385, 347-349	
	<b>AE</b>	Barker, E.L. et al., "Constitutively active 5-hydroxytryptamine <sub>2C</sub> receptors reveal novel inverse agonist activity of receptor ligands," <i>J. Biol. Chem.</i> , 1994, 269(16), 11687-11690	
	<b>AF</b>	Baxter, G., "5-HT <sub>2</sub> receptors: a family re-united?" <i>Trends Pharmacol. Sci.</i> , 1995, 16, 105-110	
	<b>AG</b>	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family," <i>Nature</i> , 1986, 320, 415	
	<b>AH</b>	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G <sub>q/11</sub> by the m3 muscarinic acetylcholine receptor," <i>J. Biol. Chem.</i> , 1995, 270, 17741-17748	
	<b>AI</b>	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in <i>Receptor-Based Drug Design</i> , Leff, P. (ed.), New York, M. Dekker, 1998, 363-377	
	<b>AJ</b>	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(21), 9921-9925	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>AK</b>	Burstein, E.S. et al., "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains," <i>Biochem. Pharmacol.</i> , 1996, 51(4), 539-544	
	<b>AL</b>	Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," <i>J. Biol. Chem.</i> , 1996, 271(6), 2882-2885	
	<b>AM</b>	Burstein, E.S. et al., "Constitutive activation of muscarinic receptors by the G-protein G <sub>q</sub> ," <i>FEBS Lett.</i> , 1995, 363(3), 261-263	
	<b>AN</b>	Bylund, D., "International union of pharmacology nomenclature of adrenoceptors," <i>Pharmacol. Rev.</i> , 1994, 46, 121-136	
	<b>AO</b>	Casey, C. et al., "Constitutively active mutant 5-HT <sub>2A</sub> serotonin receptors: inverse agonist activity of classical 5HT <sub>2A</sub> antagonists," <i>Soc. Neurosci.</i> , 1996, Abstract #699.10	
	<b>AP</b>	Cheatham, B. et al., "Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 7336-7340	
	<b>AQ</b>	Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," <i>J. Biol. Chem.</i> , 1995, 270, 23398-23401	
	<b>AR</b>	Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," <i>J. Antibiot. (Tokyo)</i> , 1993, 46(1), 131-134	
	<b>AS</b>	Chen, W. et al., "A colorimetric assay for measuring activation of G <sub>s</sub> - and G <sub>q</sub> -coupled signaling pathways," <i>Anal. Biochem.</i> , 1995, 226(2), 349-354	
	<b>AT</b>	Chidiac, P. et al., "Inverse agonist activity of β-adrenergic antagonists," <i>J. Pharm. Exp. Ther.</i> , 1994, 45, 490-499	
	<b>AU</b>	Clozel, M. et al., "In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," <i>J. Cardiovas. Pharmacol.</i> , 1993, 22(Suppl. 8), S377-S379	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. AREN-0239	Serial No. 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 6, 2001	Group Not Yet Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>AV</b>	Collesi, C. et al., "A splicing variant of the <i>RON</i> transcript induces constitutive tyrosine kinase activity and an invasive phenotype," <i>Mol. Cell. Biol.</i> , 1996, 16(2), 5518-5526		
<b>AW</b>	Cooper, C.S. et al., "Molecular cloning of a new transforming gene from a chemically transformed human cell line," <i>Nature</i> , 1984, 311, 29-33		
<b>AX</b>	De Dios, I. et al., "Effect of L-364,718 (CCK Receptor Antagonist) on Exocrine Pancreatic Secretion of Hydrocortison-Treated Rats," <i>Pancreas</i> , 1994, 9(2), 212-218		
<b>AY</b>	Desbios-Mouthon, C. et al., "Deletion of Asn <sup>281</sup> in the $\alpha$ -subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," <i>J. Clin. Endocrinol. Metab.</i> , 1996, 81(2), 719-727		
<b>AZ</b>	Di Renzo, M.F. et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," <i>Oncogene</i> , 1991, 6(11), 1997-2003		
<b>BA</b>	Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," <i>Oncogene</i> , 1992, 7, 2549-2553		
<b>BB</b>	Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism," <i>Nature Genetics</i> , 1994, 7, 396-401		
<b>BC</b>	Eggericks, D. et al., "Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase," <i>Biochem. J.</i> , 1995, 309, 837-843		
<b>BD</b>	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," <i>J. Med. Chem.</i> , 1992, 35, 3919-3927		
<b>BE</b>	Fu, M. et al., "Functional autoimmune epitope on $\alpha_1$ -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , 1994, 344, 1660-1663		
<b>BF</b>	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto-oncogene c-kit in a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of c-kit Product," <i>J. Clin. Invest.</i> , 1993, 92, 1736-1744		
<b>BG</b>	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," <i>J. Pharm. Exp. Therap.</i> , 1995, 275(1), 200-206		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. AREN-0239	Serial No. 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 6, 2001	Group Not Yet Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>BH</b>	Gitter, B. et al., "Pharmacological Characterization of LY303870: A Novel Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist," <i>J. Pharm. Exp. Therp.</i> , 1995, 275(2), 737-744	
	<b>BI</b>	Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , 1996, 87(5), 1692-1697	
	<b>BJ</b>	Hansson, J.H. et al., "Hypertension caused by a truncated epithelial sodium channel $\gamma$ subunit: genetic heterogeneity of Liddle syndrome," <i>Nat. Genet.</i> , 1995, 11(1), 76-82	
	<b>BK</b>	Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity," <i>J. Biol. Chem.</i> , 1996, 271(4), 1857-1860	
	<b>BL</b>	Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epidermal Growth Factor Receptors," <i>J. Clin. Invest.</i> , 1984, 74, 647-651	
	<b>BM</b>	Herrick-Davis, K. et al., "Constitutively Active 5HT2C Serotonin Receptor Created by Site-Directed Mutagenesis," <i>Soc. Neurosci.</i> , Abstract No. 699.18	
	<b>BN</b>	Hieble, J., "International union of pharmacology. X. Recommendation for nomenclature of 1-adrenoceptors," <i>Pharm. Rev.</i> , 1995, 47, 267-270	
	<b>BO</b>	Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," <i>Am. Soc. Pharm. Exp. Therap.</i> , 1990, 42(1), 45-83	
	<b>BP</b>	Högger, P. et al., "Activating and Inactivating Mutations in - and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," <i>J. Biol. Chem.</i> , 1995, 270(13), 7405-7410	
	<b>BQ</b>	Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene <i>c-kit</i> in Acute Myeloblastic Leukemia Cells," <i>Blood</i> , 1991, 78(11), 2962-2968	
	<b>BR</b>	Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," <i>Mol. Pharm.</i> , 1992, 42, 982-990	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. AREN-0239	Serial No. 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 6, 2001	Group Not Yet Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	BS	Jakubik, J. et al., "Constitutive activity of the M <sub>1</sub> -M <sub>4</sub> subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists," <i>FEBS Letts.</i> , 1995, 377, 275-279	
	BT	Kjelsberg, M.A. et al., "Constitutive activation of the $\alpha_{1B}$ -adrenergic receptor by all amino acid substitutions at a single site," <i>J. Biol. Chem.</i> , 1992, 267(3), 1430-1433	
	BU	Knapp, R. et al., "Molecular biology and pharmacology of cloned opioid receptors," <i>FASEB J.</i> , 1995, 9, 516-525	
	BV	Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," <i>Human Mol. Genetics</i> , 1995, 4(2), 183-188	
	BW	Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," <i>Mol. Endocrinology</i> , 1993, 7, 114-130	
	BX	Kraus, M. et al., "Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2900-2904	
	BY	Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," <i>J. Pharm. Exp. Therap.</i> , 1996, 277(2), 840-851	
	BZ	Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene c-kit Product," <i>Blood</i> , 1991, 78(11), 2834-2840	
	CA	Labbé-Jullié, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," <i>J. Pharm. Exp. Therap.</i> , 1994, 271(1), 267-276	
	CB	Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," <i>J. Clin. Endocrinol. Metabol.</i> , 1995, 80(8), 2490-2494	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>CC</b>	Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty," <i>Proc. Natl. Acad. Sci USA</i> , 1995, 92, 1906-1910
	<b>CD</b>	Løvlie, R. et al., "The Ca <sup>2+</sup> -sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism," <i>Hum. Genet.</i> , 1996, 98, 129-133
	<b>CE</b>	Lefkowitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," <i>Trends Pharmacol. Sci.</i> , 1993, 14, 300-307
	<b>CF</b>	Libermann, T. et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," <i>Nature</i> , 1985, 313, 144-147
	<b>CG</b>	Liu, C. et al., "Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas," <i>Oncogene</i> , 1992, 7, 181-185
	<b>CH</b>	Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," <i>J. Biol. Chem.</i> , 1996, 271(11), 6172-6178
	<b>CI</b>	Lonardo, F. et al., "The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," <i>New Biologist</i> , 1990, 2(11), 992-1003
	<b>CJ</b>	Maenhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological constitutive activity," <i>Biochem. Biophys. Res. Comm.</i> , 1990, 173(3), 1169-1178
	<b>CK</b>	Mann, J. et al., "Increased serotonin <sub>2</sub> and β-adrenergic receptor binding in the frontal cortices of suicide victims," <i>Arch. Gen. Psychiatry</i> , 1986, 43, 954-959
	<b>CL</b>	Marone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, 1996, Abstract No. 609.8
	<b>CM</b>	Magnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy," <i>Circulation</i> , 1994, 89, 2760-2767

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>		Docket No. AREN-0239	Serial No. 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 6, 2001	Group Not Yet Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>CN</b>	Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>Xenopus</i> Oocytes and AtT20 Cells," <i>J. Biol. Chem.</i> , 1995, 270(3), 1041-1047		
<b>CO</b>	Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization," <i>Mol. Cell. Biol.</i> , 1994, 14(7), 4843-4854		
<b>CP</b>	Nanevicz, T. et al., "Thrombin receptor activating mutations," <i>J. Biol. Chem.</i> , 1996, 271(2), 702-706		
<b>CQ</b>	Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," <i>Br. J. Cancer</i> , 1993, 68, 746-750		
<b>CR</b>	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," <i>J. Biol. Chem.</i> , 1995, 270(44), 26037-26040		
<b>CS</b>	Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," <i>J. Pharm. Exp. Ther.</i> , 1992, 263(1), 241-245		
<b>CT</b>	O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human $\beta 2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , 1988, 263(31), 15985-15992		
<b>CU</b>	Offermanns, S. et al., "G $\alpha_{15}$ and G $\alpha_{16}$ Couple a Wide Variety of Receptors to Phospholipase C," <i>J. Biol. Chem.</i> , 1995, 270, 15175-15180		
<b>CV</b>	Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," <i>J. Med. Chem.</i> , 1994, 37, 4508-4521		
<b>CW</b>	Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," <i>J. Biol. Chem.</i> , 1996, 271(14), 7949-7955		
<b>CX</b>	Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism," <i>J. Clin. Endocr. Metab.</i> , 1996, 81, 3584-3588		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. AREN-0239	Serial No. 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 6, 2001	Group Not Yet Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

CY	Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , 1993, 365, 649-651
CZ	Pei, G. et al., "A constitutive active mutant $\beta_2$ -adrenergic receptor is constitutively desensitized and phosphorylated," <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 2699-2702
DA	Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat," <i>J. Pharmacol. Exp. Ther.</i> , 1993, 265(3), 1348-1354
DB	Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," <i>CNS Drugs</i> , 1995, 4 (Suppl. 1), 18-28
DC	Pettibone, D.J. et al., "Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists," <i>Regul. Pept.</i> , 1993, 45, 289-293
DD	Prat, M.P. et al., "The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors," <i>Int. J. Cancer</i> , 1991, 49, 323-328
DE	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , 1996, 49, 422-429
DF	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and $^3$ H-acetylcholine release from guinea-pig gallbladder," <i>Neuropeptides</i> , 1993, 25(5), 271-276
DG	Ren, Q. et al., "Constitutive active mutants of the $\alpha_2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268, 16483-16487
DH	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active ET <sub>A</sub> receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , 1995, 273(3), 1410-1417
DI	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," <i>Cell</i> , 1993, 72, 827-834
DJ	Rong, S. et al., "Met expression and sarcoma tumorigenicity," <i>Cancer</i> , 1993, 53(22), 5355-5360

**EXAMINER****DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>		Docket No. AREN-0239	Serial No. 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 6, 2001	Group Not Yet Assigned
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>DK</b>	Samama, P. et al., "A mutation-induced activation state of the $\beta 2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268(7), 4625-4636	
	<b>DL</b>	Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor," <i>Am. Soc. Pharm. Exp. Ther.</i> , 1996, 50, 285-292	
	<b>DM</b>	Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338," <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73, 805-811	
	<b>DN</b>	Scheer, A. et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Rec. Signal Transduct. Res.</i> , 1997, 17(1-3), 57-73	
	<b>DO</b>	Scheer, A. et al., "The activation process of the $\alpha_{1B}$ -adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94, 808-813	
	<b>DP</b>	Schwinn, D.A. et al., "Cloning and pharmacological characterization of human <i>Alpha-1</i> adrenergic receptors: sequence corrections and direct comparison with other species homologues," <i>J. Pharmacol.</i> , 1995, 272(1), 134-142	
	<b>DQ</b>	Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the <i>Xenopus laevis</i> oocyte expression system," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 5699-5703	
	<b>DR</b>	Seeman, P. et al., "Dopamine receptor pharmacology," <i>Trends Pharmacol. Sci.</i> , 1994, 15, 264-270	
	<b>DS</b>	Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," <i>Nature</i> , 1993, 365, 441-445	
	<b>DT</b>	Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin $V_{1a}$ receptors," <i>J. Clin. Invest.</i> , 1993, 92, 224-231	
	<b>DU</b>	Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors," <i>Mol. Cell. Endocrinology</i> , 1994, 100, 115-119	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>DV</b>	Showers, M.O. et al., "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation," <i>Blood</i> , 1992, 80(12), 3070-3078	
	<b>DW</b>	Skinner, R.H. et al., "Direct measurement of the binding of RAS to neurofibromin using scintillation proximity assay," <i>Anal. Biochem.</i> , 1994, 223, 259-265	
	<b>DX</b>	Slamon, D.J. et al., "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene," <i>Science</i> , 1987, 235, 177-182	
	<b>DY</b>	Slamon, D. et al., "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer," <i>Science</i> , 1989, 244, 707-712	
	<b>DZ</b>	Solomon, Y. et al., "A highly sensitive adenylate cyclase assay," <i>Anal. Biochem.</i> , 1974, 58, 541-548	
	<b>EA</b>	Spiegel, A.M., "Defects in G protein-coupled signal transduction in human disease," <i>Ann. Rev. Physiol.</i> , 1995, 58, 143-170	
	<b>EB</b>	ter Laak, A. et al., "Modelling and mutation studies on the histamine H <sub>1</sub> -receptor agonist binding site reveal different binding modes for H <sub>1</sub> -agonists: Asp <sup>116</sup> (TM3) has a constitutive role in receptor stimulation," <i>J. Computer-Aided Mol. Design</i> , 1995, 9, 319-330	
	<b>EC</b>	Tiberi, M. et al., "High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype," <i>J. Biol. Chem.</i> , 1994, 269(45), 27925-27931	
	<b>ED</b>	Tsujimura, T. et al., "Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain," <i>Blood</i> , 1996, 87(1), 273-283	
	<b>EE</b>	Wang, Z. et al., "Constitutive $\mu$ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence," <i>Life Sci.</i> , 1994, 54(20), 339-350	
	<b>EF</b>	Watowich, S.S. et al., "Homodimerization and constitutive activation of the erythropoietin receptor," <i>Proc. Natl. Acad. Sci USA</i> , 1992, 89, 2140-2144	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>EG</b>	Weber-Nordt, R.M. et al., "Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines," <i>Blood</i> , 1996, 88(3), 809-816	
	<b>EH</b>	Webster, M.K. et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane point mutation found in achondroplasia," <i>EMBO J.</i> , 1996, 15, 520-527	
	<b>EI</b>	Xu, Y. et al., "Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines," <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81, 7308-7312	
	<b>EJ</b>	Yamada, K. et al., "Substitution of the insulin receptor transmembrane domain with the <i>c-neu/erbB2</i> transmembrane domain constitutively activates the insulin receptor kinase <i>in vitro</i> ," <i>J. Biol. Chem.</i> , 1992, 267(18), 12452-12461	
	<b>EK</b>	Zhang, S. et al., "Identification of Dynorphins as Endogenous Ligands for an Opioid Receptor-Like Orphan Receptor," <i>J. Biol. Chem.</i> , 1995, 270, 22772-22778	
	<b>EL</b>	Zhen, Z. et al., "Structural and functional domains critical for constitutive activation of the HGF-receptor ( <i>Met</i> )," <i>Oncogene</i> , 1994, 9, 1691-1697	
	<b>EM</b>	Pauwels P.J. et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors", <i>Molecular Neurobiology</i> , 1998, 17, pp. 109-135.	
	<b>EN</b>	Shryock, John et al., "Inverse Agonists and Neutral Antagonists of Recombinant Human A <sub>1</sub> Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells," <i>Molecular Pharmacology</i> , 1998, 53, pp. 886-893.	
	<b>EO</b>	Wenzel-Seifert et al., "High Constitutive Activity of the Human Formyl Peptide Receptor", <i>Journal of Biological Chem.</i> , 1998, 273, pp. 24181-24189.	
	<b>EP</b>	Forman, B.M., et al., "Androstanone Metabolites Bind to and Deactivate the Nuclear Receptor CAR-β", <i>Nature</i> , 1998, 395, pp. 612-615.	
	<b>EQ</b>	Seifert R. et al., "Different Effects of G <sub>α</sub> Splice Variants on β <sub>2</sub> -Adrenoreceptor-mediated Signaling, <i>Journal of Biological Chem.</i> , 1998, 273, pp. 5109-5116.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>ER</b>	Bergsma, D.J., et al., "Cloning and characterization of a human angiotensin II type 1 receptor," <i>Biochem. &amp; Biophys. Res. Comm.</i> , 1992, XP-002145165, 183(3), 989-995	
	<b>ES</b>	Gantz, I., et al., "Molecular cloning, expression, and gene localization of a fourth melanocortin receptor," <i>J. Biol. Chem.</i> , 1993, XP-002051983, 268(20), 15174-15178	
	<b>ET</b>	Groblewski, T., et al., "Mutation of Asn <sup>111</sup> in the third transmembrane domain of the AT <sub>1a</sub> angiotensin II receptor induces its constitutive activation," <i>J. Biol. Chem.</i> , 1997, XP-002145162, 272(3), 1822-1826	
	<b>EU</b>	Koike, G., et al., "Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung," <i>Biochem. And Biophys. Res. Comm.</i> , 1994, XP-002145166, 203(3), 1842-1850	
	<b>EV</b>	Kyaw, H., et al., "Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene," <i>DNA and Cell Biology</i> , 1998, XP000929737, 17(6), 493-500	
	<b>EW</b>	Noda, K., et al., "The active state of the AT <sub>1</sub> angiotensin receptor is generated by angiotensin II induction," <i>Biochem.</i> , 1996, XP-002145163, 35, 16435-16442	
	<b>EX</b>	Reppert, S.M., et al., "Cloning of a melatonin-related receptor from human pituitary," <i>FEBS Letts.</i> , 1996, XP-002145161, 219-2254	
	<b>EY</b>	Scheer, A., et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Receptor &amp; Signal Transduction Res.</i> , 1997, XP-000867531, 17(1-3), 57-73	
	<b>EZ</b>	Munzy D. et al., "Homo sapiens chromosome 2p13.3, clone RPCI111-433J6 - sequencing in progress - 100 unordered pieces." <i>EMBL Database Accession Number AC006087</i> , 1998.	
	<b>FA</b>	Smith D.R., "Sequencing of human chromosome 10", <i>EMBL Database Accession Number AC005849</i> , 1998.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>FB</b>	O'Dowd B.F. et al., "Discovery of Three Novel G-Protein-Coupled Receptor Genes", <i>Genomics</i> , 1998, 47, pp. 310-313. (Whole document)	
	<b>FC</b>	Strausberg R., "National Cancer Institute, Cancer Genome Anatomy Project", <i>EMBL Database Accession Number AI090920</i> , 1998. (Abstract)	
	<b>FD</b>	Matsuoka I. et al., "Identification of Novel members of G-protein coupled receptor subfamily", <i>Biochemical and Biophysical Research Communications</i> , 1993, 194. (whole document)	
	<b>FE</b>	Hillier L. et al., "Generation and analysis of 280000 human expressed sequence tags", <i>EMBL Database Accession Number H67224</i> , 1995, abstract.	
	<b>FF</b>	Strausberg R., "National Cancer Institute, Cancer Genome Project", <i>EMBL Database Accession Number AI131555</i> , 1998, abstract.	
	<b>FG</b>	Weng et al., "A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M", <i>Proceedings of the National Acad. Of Sciences of USA</i> , 1998, 95, whole document.	
	<b>FH</b>	Strausberg R., "National Cancer Institute, Cancer Genome Anatomy Project", <i>EMBL Database Accession Number AA804531</i> , 1998, abstract.	
	<b>FI</b>	Stadel, et al., "Orphan G Protein-Coupled Receptors: A neglected opportunity for pioneer drug discovery", <i>Trends in Pharm. Sciences</i> , 1997, 18, pp. 430-437.	
	<b>FJ</b>	Williams, S., "Human DNA Sequence From close 417022 on Chromosome 6q16.1-16.3.", <i>EMBL Database Entry HS417022</i> , 1998, pp. 1-34.	
*	<b>FK</b>	Nichols, J.G. et al. (eds), "Indirect mechanisms of synaptic transmission", <i>From Neuron to Brain</i> , 3 <sup>rd</sup> edition, Sinauer Associates, Inc., 1992	
*	<b>FL</b>	Oslo et al. (Eds), <i>Remington's Pharmaceutical Sciences</i> , 16 <sup>th</sup> edition, Mack Publishing Co., 1980	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>FM</b>	Gantz, I. et al., "Molecular cloning of a novel melanocortin receptor", <i>J. Biol. Chem.</i> , 1993, 268(11), pp 8246-8250	
	<b>FN</b>	Howard, A.D. et al., "A receptor in pituitary and hypothalamus that functions in growth hormone release", <i>Science</i> , 1996, 273, pp 974-977	
	<b>FO</b>	Iismaa, T.P. et al., "Isolation and chromosomal localization of a novel human G-protein-coupled receptor (GPR3) expressed predominately in the central nervous system", <i>Genomics</i> , 1994, 24, pp391-394	
	<b>FP</b>	Heiber, M. et al., "Isolation of three novel melanocortin receptor", <i>J. Biol. Chem.</i> , 1993, 26(11), pp 8246-8250	
	<b>FQ</b>	Bertin, B. et al., "Cellular signaling by an agonist-activated receptor/Gs-alpha fusion protein", <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, pp 8827-8831	
	<b>FR</b>	Wise, A. et al., "Rescue of functional interaations between the alpha-2-A-adrenoreceptor and acylation-resistant forms of Gil-alpha by expressing the proteins from chimeric open reading frames", <i>J. Biol Chem.</i> , 1997, 272, pp 24673-24678	
	<b>FS</b>	Burt, A.R., et al. "Agonist occupation of an alpha-2-A-adreroreceptor-Gil-alpha fusion protein results in activation of both receptor-linked and endogenes Gi proteins", <i>J. Biol. Chem.</i> , 1997, 283, pp 10367-10375	
	<b>FT</b>	Jensen et al., "mRNA profiling of rat islet tumors reveals Nkx 6.1 as a Cell-specific homeodomain transcription factor", <i>J. Biol. Chem.</i> , 1996, 271(31), pp 18749-18758	
	<b>FU</b>	Konig et al., "Method for identifying ligands that bind to cloned Gs-orGi-coupled receptors", <i>Mol. Cell. Neuro.</i> , 1991, 2, pp331-337	
	<b>FV</b>	Leonard, J. et al., "The LIM family transcription factor Isl-1 requires cAMP response element binding protein to promote somatostatin expression in pancreatic islet cells", <i>Proc Natl. Acad. Sci. USA</i> , 1992, 89, pp 6247-6251	
	<b>FW</b>	Marchese, A. et al., "Cloning of human genes encoding novel G protein-coupled receptors", <i>Genomics</i> , 1994, 23, pp 609-618	
	<b>FX</b>	Marks, D.L. et al., "Simultaneous visualization of two cellular mRNA species in individual neurons by use of a new double <i>in situ</i> hybridization method", <i>Mol. &amp; Cell. Neuro</i> , 1992, 3, pp 395-405	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. AREN-0239	Serial No. 09/875,076
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>FY</b>	O'Dowd, B. et al., "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes", <i>Gene</i> , 1997, 187, pp75-81	
	<b>FZ</b>	Sakuri, T. et al., "Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior", <i>Cell</i> , 1998, 92, pp 573-585	
	<b>GA</b>	Song, Z.H., et al. "Molecular cloning and chromosomal localization of human genes encoding three closely related G-protein-coupled receptors", <i>Genomics</i> , 1995, 28, pp 347-349	
	<b>GB</b>	Suzuki, M. et al., "Regulatable promoters for use in gene therapy applications: Modification of the 5'-flanking region of the CFTR gene with multiple cAMP response elements to support basal, low level gene expression that can be upregulated by exogenous agents that raise intracellular levels of cAMP", <i>Human Gene Therapy</i> , 1996, 7, pp 1883-1893	
	<b>GC</b>	Xu, Y. et al., "Identification of human OGR1, a novel G Protein-coupled receptor that maps to chromosome 14", <i>Genomics</i> , 1996, 35, pp 397-402	
	<b>GD</b>	Gellai, M. et al., "Nonpeptide endothelin receptor antagonists V: prevention and reversal of acute renal failure in the rat by SB 209670", <i>J. Pharm. Exp. Therap.</i> , 1995, 275(1), pp 200-206	
	<b>GE</b>	Heiber, M. et al., "Isolation of three novel human genes encoding G protein-coupled receptors", <i>DNA and Cell Biology</i> , 1995, 14(1), pp 25-35	
	<b>GF</b>	Itoh, H. et al., "Molecular cloning and sequence determination of cDNAs for subunits of the guanine nucleotide-binding proteins Gs, G1, and G0 from rat brain", <i>Proc. Natl. Acad. Sci. USA</i> , 1986, 83, pp 3776-3780	
	<b>GG</b>	Kenakin, T., "Are receptors promiscous? Intrinsic efficacy as a transduction phenomenon", <i>Life Sciences</i> , 1998, 43, pp 1095-1101	
	<b>GH</b>	Martone, R.L. et al. "Human CRF receptor chimeras: Mapping of ligand binding determinants", 26 <sup>th</sup> meeting of the society of Neuroscience, Washington, D.C., November 16-21, 1996, Abstract No. 609.8	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	<b>GI</b>	5,514,578	05/07/96	Hogness et al.	435	240.2
	<b>GJ</b>	5,532,157	07/02/96	Fink	435	240.2
	<b>GK</b>	5,573,944	11/12/96	Kirschner et al.	435	252.3
	<b>GL</b>	5,639,616	06/17/97	Liao et al.	435	7.1
	<b>GM</b>	5,750,353	05/12/98	Kopin et al.	435	7.21

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	<b>GN</b>	WO 97/11159	09/20/96	PCT	X	
	<b>GO</b>	WO 98/46995	10/22/98	PCT	X	
	<b>GP</b>	WO 99/52927	10/21/99	PCT	X	
	<b>GQ</b>	WO 98/00552	01/08/98	PCT	X	
	<b>GR</b>	WO 98/34948	08/13/98	PCT	X	

EXAMINER	DATE CONSIDERED



<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0239</b>	Serial No. <b>09/875,076</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Ruoping Chen, et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>June 6, 2001</b>	Group <b>Not Yet Assigned</b>

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	<b>GW</b>	WO 00 23588	04/27/00	PCT	X	
	<b>GX</b>	WO 99 55732	04/11/99	PCT	X	
	<b>GY</b>	WO 99 46378	09/16/99	Japan	X(abstract)	
	<b>GZ</b>	WO 98 39441	09/11/98	PCT	X	
	<b>HA</b>	WO 99 24463	05/20/99	PCT	X	
	<b>HB</b>	EP 0 899 332	03/03/99	EPO	X	
	<b>HC</b>	WO 00 26369	05/11/00	PCT	X	
	<b>HD</b>	WO 99 52946	10/21/99	PCT	X	
	<b>HE</b>	WO 98 31810	07/23/98	PCT	X	
	<b>HF</b>	EP 0 860 502	08/26/98	EPO	X	
	<b>HG</b>	WO 99 25830	05/27/99	PCT	X	
	<b>HH</b>	WO 99 55734	11/04/99	PCT	X	
	<b>HI</b>	WO 00 12707	03/09/00	PCT	X	
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		

<b>Form PTO-1449 Modified</b>			Docket No. AREN-0239	Serial No. 09/875,076		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant <b>Ruoping Chen, et al.</b>			
U.S. Department of Commerce Patent and Trademark Office			Filing Date June 6, 2001	Group Not Yet Assigned		
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initial		Document No.	Date	Name	Translation YES	NO
	<b>HJ</b>	WO 00 11170	03/02/00	PCT	X	
	<b>HK</b>	WO 00 11166	03/02/00	PCT	X	
	<b>HL</b>	WO 98 50549	11/12/98	PCT	X	
	<b>HM</b>	WO 00 28028	05/18/00	PCT	X	
	<b>HN</b>	WO 99 42484	08/26/99	PCT	X	
	<b>HO</b>	WO 97 20045	06/05/97	PCT	X	
	<b>HP</b>	WO 97 24929	07/17/97	PCT	X	
	<b>HQ</b>	WO 00 11015	03/02/00	PCT	X	
	<b>HR</b>	WO 98 46995	10/22/98	PCT	X	
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		

Application No.

09/1876,076

Applicant

Chen et al.

Examiner

Prabhakar Mengi

Group Art Unit

1646

Page 1 of 1

## References Cited

Central General Primary Search

## U.S. PATENT DOCUMENTS

DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS
B	7/10/98	Jokit, Jacqueline S., et al. and Andrzej Kolinski		
C				
D				
E				
F	Structural genomics project	claim to solve the experimental structure of proteins		
G	Collaboration between molecular biology and structural biology	using molecular biology to determine the structure of proteins	Collaboration	
H	Protein structure	using a novel way of exerting certain structure to do function can be used to design	Protein	
I	biochemistry	using a novel way of exerting certain structure to do function can be used to design	Biochemistry	
J				
K				
L				
M				

## FOREIGN PATENT DOCUMENTS

*	DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUBCLASS
N						
O						
P						
Q						
R						
S						
T						

## NON-PATENT DOCUMENTS

*	DOCUMENT (Including Author, Title, Source, and Pertinent Pages)	DATE
U	Skolnick et al. Nature Biotechnology Vol. 18, pages 283-287	3/00
V	current news, newspaper, magazine	
W		
X		

\* A copy of this reference is not being furnished with this Office action.  
(See Manual of Patent Examining Procedure, Section 707.05(a).)

Part of Paper No. 11